Suggested remit - to appraise the clinical and cost effectiveness of Pembrolizumab within its marketing authorisation for treating untreated, locally advanced or metastatic, triple negative breast cancer
 
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 1546

Provisional Schedule

Final draft guidance 25 May 2022 - 10 June 2022
Expected publication 29 June 2022

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Merck Sharp & Dohme
Patient carer groups Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Breast Cancer Group
  UK Clinical Pharmacy Association
Comparator companies Janssen-Cilag
  Pfizer
  Roche
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
12 April 2022 Committee meeting: 2
08 March 2022 - 29 March 2022 Draft guidance
15 February 2022 Committee meeting: 1
24 November 2021 The committee meeting for this appraisal has been scheduled for 15 February 2022.
05 May 2021 Following an update from the company, NICE will reschedule this appraisal and the committee meeting scheduled for 6 July 2021 will now take place at a later date. This webpage will be updated when the new dates are confirmed.
27 October 2020 Invitation to participate
16 September 2020 - 07 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 June 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late October 2020 when we will write to you about how you can get involved.
28 November 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late- May 2020 when we will write to you about how you can get involved.
10 June 2019 - 08 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual